Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04691502 and Exemestane in ER+/HER2- Advanced Breast Cancer
NCT01658176Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of PF-04691502 in breast cancer, sponsored by Pfizer. Planned start Jan 2013; status: withdrawn.
02
Drugs
PF-04691502
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01658176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658176.